Drug Trial Radar · NCT07422610
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
May 19, 2026
Primary completion
Jun 28, 2028
Study completion Aug 2, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver function. To reduce participant burden and maximize benefit, the PK of pelabresib will be assessed at steady-state rather than after a single dose, avoiding treatment-free washout periods.
Conditions
- Advanced Malignancies and Hepatic Impairment
Interventions
pelabresibDrug
pelabresib 125 mg orally (PO) once daily (QD) for 14 days, followed by a 7-day break
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve from 0 to 24 hours on Day 14 (AUC₀-24h,D14) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14: 0, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose (1 cycle = 21 days)
- Maximum Plasma Concentration on Day 14 (Cmax,D14) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14 (1 cycle = 21 days)
- Apparent Clearance (CL/F) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14 (1 cycle = 21 days)
- Apparent Volume of Distribution (V/F) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14 (1 cycle = 21 days)
- Terminal Half-Life (T½) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14 (1 cycle = 21 days)
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Bordeaux, France · Recruiting
Novartis Investigative Site
Saint-Herblain, France · Recruiting
Novartis Investigative Site
Milan, MI, Italy · Recruiting
Novartis Investigative Site
Milan, MI, Italy · Recruiting
Novartis Investigative Site
Candiolo, TO, Italy · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Pozuelo de Alarcón, Madrid, Spain · Recruiting
Novartis Investigative Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.